PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: AN2728 Cream, 1%Drug: AN2728 Cream, 0.3%Drug: AN2728 Cream VehicleDrug: AN2728 Cream, 2%Drug: Betnesol®-V Creme, 0.1%
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00763204
- Locations
- 🇩🇪
Bioskin GmbH, Hamburg, Germany
A Study to Investigate the Anti-Plaque Effect of AN0128 Toothpaste
Phase 1
Completed
- Conditions
- Dental Plaque
- Interventions
- Drug: Prototype (AN0128 Toothpaste)Other: Negative Control (Regular Toothpaste)Other: Positive Control (anti-plaque/anti-bacterial toothpaste)
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT00762151
- Locations
- 🇺🇸
Concordia Research Laboratories, Cedar Knolls, New Jersey, United States
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
Phase 3
Completed
- Conditions
- Healthy Subjects
- Interventions
- Biological: 13 valent pneumococcal conjugate vaccine
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1200
- Registration Number
- NCT00761631
- Locations
- 🇺🇸
Pfizer Investigational Site, Monroe, Wisconsin, United States
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT00761267
- Locations
- 🇧🇷
Hospital Pequeno Principe, Curitiba, PR, Brazil
🇰🇷Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
🇺🇸University of California - Los Angeles - Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: AN2728Drug: AN2728 Ointment Vehicle
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00759161
- Locations
- 🇲🇽
IMIC, Mexico City, Distrito Federal, Mexico
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Phase 1
Completed
- Conditions
- Pneumonia
- Interventions
- Drug: CP-70,429 and PF-03709270
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00759564
- Locations
- 🇺🇸
Centurion Clinical Research, Indianapolis, Indiana, United States
🇧🇪Pfizer Clinical Research Unit, Bruxelles, Belgium
Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Completed
- Conditions
- Pneumococcal Disease
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28511
- Registration Number
- NCT00757575
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Ointment vehicleDrug: AN2728
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00755196
- Locations
- 🇲🇽
IMIC, Mexico City, Distrito Federal, Mexico
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
Phase 3
Terminated
- Conditions
- Fibromyalgia
- Interventions
- Drug: [S,S]-Reboxetine
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 390
- Registration Number
- NCT00754221
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Phase 2
Completed
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 204
- Registration Number
- NCT00752219
- Locations
- 🇺🇸
Cedars-Sinai Medical Center Dept of Surgery, Los Angeles, California, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸University of Southern California, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath